Drug Type Small molecule drug |
Synonyms Fobrepodacin, Fobrepodacin(USAN) |
Target |
Mechanism Bacterial DNA gyrase inhibitors |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC21H26FN6O6P |
InChIKeyCOTQDURISRILOR-CQSZACIVSA-N |
CAS Registry1384984-31-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mycobacterium Infections, Nontuberculous | Phase 2 | US | 14 Dec 2022 | |
Lung Diseases | Phase 2 | US | 03 Dec 2020 | |
Mycobacterium Avium-Intracellulare Infection | Phase 2 | US | 03 Dec 2020 |
GlobeNewswire Manual | Phase 2 | 16 | kytswnaorm(pmjyxhsard) = In evaluating the totality of both the efficacy and safety data, the Company has elected to suspend its current development program for SPR720 and will evaluate other potential paths forward as the remaining data are collected and analyzed. xazxzogche (iiksysmovn ) Not Met | Negative | 29 Oct 2024 | ||
NCT05955586 (Pubmed) Manual | Phase 1 | - | 30 | hrfunofqxd(qiwfuxvgvj) = When corrected for protein binding, the ratios of ELF to unbound plasma concentrations of SPR719 for AUC0-24 and Cmax were 19.87 and 21.88, and the ratios of AM to unbound plasma concentrations of SPR719 for AUC0-24 and Cmax were 42.50 and 52.53, respectively. omyixkqhur (zwhqghzolv ) View more | Positive | 01 Oct 2024 | |
Phase 2 | 2 | Placebo | bthlyzdadz(bfcwkwgdsd) = lggdebhdwa olexcfqmkv (nigdddacot, blgmrnmqnt - qwpxduddcb) View more | - | 28 Feb 2022 | ||
Phase 1 | 96 | twkngozcwn(qdfmucltdb) = qbjjhquzcl qhtboxxjkj (qoxshnwjzp ) | Positive | 18 Oct 2021 |